Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cancer Research UK Phase I/II Open Label Study to Evaluate the Safety, Endocrine Effects and Anti-tumour Activity of Abiraterone Acetate (CB7630) in Patients With Oestrogen (ER) or Androgen Receptor (AR) Positive Advanced or Metastatic Breast Carcinoma

NCT00755885 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.

NCT NCT00755885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00755885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cancer Research UK Phase I/II Open Label Study to Evaluate the Safety, Endocrine Effects and Anti-tumour Activity of Abiraterone Acetate (CB7630) in Patients With Oestrogen (ER) or Androgen Receptor (AR) Positive Advanced or Metastatic Breast Carcinoma
Lead sponsor
Cancer Research UK
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2008
Completion date
June 4, 2016
Enrollment
77 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer